Skip to main content

Hospitals: Infectious Diseases

Volume 475: debated on Friday 16 May 2008

To ask the Secretary of State for Health what steps are being taken to implement the Rapid Review Panel recommendations on healthcare technologies capable of reducing healthcare-acquired infection into clinical practice at trust level; what budget has been allocated for this purpose; and how uptake of such technologies will be monitored. (204116)

A wide range of new programmes is being implemented to support the Rapid Review Panel as a consequence of the Healthcare Associated Infection Technology Innovation Programme launched in the Clean, safe care strategy (January 2008). Copies of the strategy are available in the Library. Technologies with a Rapid Review Panel recommendation 1 are being placed in showcase hospitals around the country for periods up to six months for the purpose of evaluating in-use features and providing feedback to the national health service in the form of ready made adoption business cases. Such technologies are also subject to an accelerated placement in the NHS supply chain catalogue.

The budget for the first phase is still being finalised as discussions with suppliers are ongoing but indicative costs for the purchase of technologies are estimated to be £1.4 million and the cost of providing local NHS expertise to manage the projects at the hospitals is £700,000 for a 12 month period.

Uptake will be reviewed through information provided by the NHS supply chain where this is appropriate. Plans are also being developed to provide support to technologies that have Rapid Review Panel 2 and 3 recommendations.

To ask the Secretary of State for Health how many product assessments the Rapid Review Panel has undertaken since December 2003; how many assessed products were recommended to his Department for use (a) in the NHS and (b) by the NHS Purchasing and Supplies Agency; and how many products in use by the NHS were recommended by the panel. (205204)

The Rapid Review Panel (RRP) has undertaken 207 assessments since its first meeting.

Seven products have demonstrated sufficient basic research and development, validation and recent in use evaluations to enable the RRP to make a recommendation to the Department that the product should be made available to national health service bodies. This is a recommendation one.

Of the seven products given a recommendation one, six products have been made available to the NHS by the NHS Purchasing and Supply Agency via the NHS Supply Chain and are contained in their product supply catalogue.

The Department does not have full information on the use of these three recommendation one products as infection control products do not have to be purchased through NHS Supply Chain. NHS trusts are free to choose which products to purchase and will maintain their own records.

The NHS Purchasing and Supplies Agency does not recommend particular products.